Navigation Links
Once-Daily Combo Works for New HIV Patients
Date:8/2/2008

Tazanavir/ritonavir as good as twice-daily dose of lopinavir/ritonavir, study says

FRIDAY, Aug. 1 (HealthDay News) -- Once-daily treatment with tazanavir/ritonavir (A/R) is as effective as twice-daily treatment with lopinavir/ritonavir (L/R) in HIV patients who are starting antiretroviral treatment for the first time, a European study shows.

Based on their findings, the researchers recommended once-daily A/R as a first-line treatment option for treatment-naive HIV patients since it has a number of advantages over the currently recommended twice-daily L/R.

The study included 883 treatment-naive HIV patients who were randomly assigned to receive A/R 300/100 milligrams once daily (440 patients) or L/R 400/100 milligrams twice daily (443 patients). Both regimens were in combination with tenofovir/emtricitabine 300/200 once daily, as is standard.

After 48 weeks of treatment, 78 percent of patients receiving A/R and 76 percent of those receiving L/R had a viral load of less than 50 copies per milliliters in their blood, and both groups showed similar increases in the numbers of immune system CD4 cells. Six percent of patients in both groups failed on the treatments, and two patients in the A/R group developed resistance mutations to treatment, compared with none in the L/R group.

Serious side effects were reported in 12 percent of the A/R patients and 10 percent of the L/R patients, but fewer A/R patients experienced treatment-related diarrhea (2 percent vs. 11 percent) and nausea (4 percent vs. 8 percent). None of the L/R patients developed jaundice, which occurred in 4 percent of A/R patients.

"In treatment-naive patients, atazanavir/ritonavir once-daily demonstrated similar antiviral efficacy to lopinavir/ritonavir twice daily, with less gastrointestinal toxicity but with a higher rate of hyperbilirubinaemia...the results of this study support the use of once-daily atazanavir/ritonavir as a recommended first-line treatment option, with a number of patient benefits over the currently recommended ritonavir-boosted twice-daily lopinavir for the treatment of HIV-infected antiretroviral-naive patients," the researchers concluded.

The study appears online in The Lancet, and was expected to be published in an upcoming print edition of the journal.

More information

The American Academy of Family Physicians has more about HIV medicines.



-- Robert Preidt



SOURCE: The Lancet, news release, Aug. 2, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Labopharms Once-Daily Tramadol Product Launched in South Korea, Australia, Romania and Austria
2. New Data Highlights Positive Results of Namenda (Memantine HCl) Once-Daily Extended-Release Formulation
3. FDA accepts Labopharms response for once-daily tramadol as complete Class 2 response
4. Labopharm Reaquires UK Sales And Marketing Rights to Its Once-Daily Tramadol Product
5. Labopharm Submits Complete Response to FDA as a Result of Outcome of Appeal Process for Once-Daily Tramadol
6. Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product
7. FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults
8. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
9. Once-Daily Insulin Shot Proves Effective in Study
10. A Once-Daily Oral Drug for Chronic Obstructive Pulmonary Disease That Treats COPD-Related Inflammation Could Achieve Blockbuster Status
11. Labopharms Once-Daily Tramadol Approved in South Korea and Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , ... May 04, 2016 , ... ... brand will provide the playing surface for the 2016 NCAA Men’s ... installed today for the men’s volleyball championship to be held May 5-7 at ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... provider serving families of Camas and Vancouver, WA, has announced the latest ... the National Breast Cancer Foundation and their Mammography Program, which provides free ...
(Date:5/4/2016)... ... 2016 , ... Level 10 Head Over Heels Athletic Arts’ gymnast Alessandra Brovedani ... Arizona for the fall of 2019. , After a handful of college visits, ... GymCats came from her connection with the coaching staff and the excitement surrounding Wildcat ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... Todd Rider's research and development of DRACO broad-spectrum antiviral therapeutics. DRACOs have proven ... that starts on May 3, 2016 at http://igg.me/at/EndTheVirus and runs for ...
(Date:5/4/2016)... ... May 04, 2016 , ... Olshan Properties ... real estate proudly announced that its service-based charitable program, Olshan Outreach, successfully raised ... will continue Olshan Properties’ annual philanthropic tradition in 2016 with the ‘Fight Against ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... Norgine B.V. und ... entscheidenden Meilenstein durch diese Veröffentlichung zur  Hepatischen ... um Patientenresultate  bei Verdauungs- und Lebererkrankungen zu ... Verständnis der Hepatischen Enzephalopathie bei und hebt ... Enzephalopathie in der Öffentlichkeit zu schaffen und ...
(Date:5/2/2016)... , May 2, 2016 Leading Economies with Fastest ... 10.2 Côte d,Ivoire 8.6 Uzbekistan 8 Ireland 7.8 India 7.3, , ... BRICS nations , which comprises of Brazil , ... and South Africa , registered the fastest GDP growth ... in China , recession in Brazil ...
(Date:5/2/2016)... Mass. , May 2, 2016  While nearly ... that osteoporosis can have on their health, only about ...   according to the results of a new survey ... To mark the start of National Osteoporosis Month, Hologic ... health, which affects nearly 56 million Americans. ...
Breaking Medicine Technology: